2025-524832-20-00
Recruiting
Phase 1
A PHASE 1, OPEN-LABEL STUDY TO ASSESS THE ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION, INCLUDING THE MASS BALANCE, OF A SINGLE ORAL DOSE OF [14C]-VAFIDEMSTAT IN HEALTHY MALE PARTICIPANTS
Oryzon Genomics S.A.0 sites8 target enrollmentStarted: July 1, 2026Last updated:
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Oryzon Genomics S.A.
- Enrollment
- 8
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Chief Scientific Officer
Scientific
Oryzon Genomics S.A.
Similar Trials
Not yet recruiting
Not Applicable
A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer*Urothelial Cancer
*Advanced/Metastatic Urothelial Cancer
*Urothelial CarcinomajRCT2021250056132
Not yet recruiting
Not Applicable
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers*Advanced/Metastatic Non-Small Cell Lung CancerjRCT2031250706162
Completed
Phase 1
A Phase I, Open-Label Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose2022-500921-34-00Achieve Life Sciences Inc.56
Recruiting
Phase 1
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications2023-506227-29-00AbbVie Deutschland GmbH & Co. KG60
Not yet recruiting
Phase 1
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors2025-523165-19-00BeOne Medicines I GmbH15